Effects of 1,8-Cineole on Diabetic Muscular Atrophy

Area of Science:

• Biochemistry
• Pharmacology
• Physiology

Background:

• Diabetic muscular atrophy is a significant complication of diabetes.
• Streptozotocin (STZ)-induced diabetes in rats is a common model for studying diabetic complications.
• 1,8-cineole is a natural compound with potential therapeutic properties.

Purpose of the Study:

• To investigate the effects of 1,8-cineole on diabetic muscular atrophy in STZ-induced diabetic rats.
• To evaluate the impact of 1,8-cineole on biochemical markers of muscle damage, inflammation, and oxidative stress.

Main Methods:

• Adult male rats were induced with diabetes using STZ.
• Diabetic rats were treated with 1,8-cineole for 21 days.
• Blood and skeletal muscle samples were analyzed for glucose levels, inflammatory markers, atrophy biomarkers, oxidative stress markers, and glucose transporter expression.

Main Results:

• STZ-induced diabetes increased blood glucose, inflammation (TGF-β1, TNF-α), muscle atrophy markers (FBXO32, MuRF1), and oxidative stress (MDA), while decreasing glucose transporter 4 (GLUT4).
• 1,8-cineole treatment reversed these diabetes-induced changes, including reducing MDA levels and increasing GLUT4 expression.
• Skeletal muscle antioxidant enzyme activity (SOD) was not significantly altered by diabetes or 1,8-cineole treatment.

Conclusions:

• 1,8-cineole demonstrates protective effects against diabetic muscular atrophy.
• The compound mitigates muscle damage by reducing oxidative stress, inflammation, and proteolytic gene expression.
• 1,8-cineole enhances glucose uptake and insulin sensitivity, suggesting its therapeutic potential for diabetic muscle complications.